Investing.com - Edgewise Therapeutics (NASDAQ: EWTX) reported first quarter EPS of $-0.36, in line with the analyst estimate of $-0.36. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.
Edgewise Therapeutics's stock price closed at $9.91. It is down -0.20% in the last 3 months and up 27.18% in the last 12 months.
Edgewise Therapeutics saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Edgewise Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Edgewise Therapeutics's Financial Health score is "fair performance".
Check out Edgewise Therapeutics's recent earnings performance, and Edgewise Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar